37 results on '"Fernandez-Montes A"'
Search Results
2. State of the scientific evidence and recommendations for the management of older patients with gastric cancer
3. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
4. Energy policies for data-center monolithic schedulers
5. Public resource usage in health systems: a data envelopment analysis of the efficiency of health systems of autonomous communities in Spain
6. Application of calcium phosphates and fibronectin as complementary treatment for osteoporotic bone fractures
7. Evaluating decision-making performance in a grid-computing environment using DEA
8. Smart scheduling for saving energy in grid computing
9. An integrated framework for harmonizing definitions of deforestation
10. P-165 Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter?
11. 1671P Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
12. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
13. 604P Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
14. 560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial
15. 126P Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
16. P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trial
17. P-221 Prediction of colon cancer recurrence based on proteomic biomarkers
18. P-122 Vitamin D-based score in gastric cancer
19. P-63 Efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: The CORE study
20. 1410P Gastric cancer: Data from the AGAMENON-SEOM study
21. 1394P Frequentist and Bayesian analysis of second line treatment effectiveness in AGAMENON-SEOM gastric cancer registry
22. 1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients
23. 1847P Professional standing of young medical oncologists in Spain during COVID-19 pandemic: A nationwide survey by the Spanish Society of Medical Oncology (SEOM) +MIR Section
24. P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study
25. P-34 Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors
26. 11P Molecular profiling and targeted therapy in cholangiocarcinoma
27. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
28. P-41 Understanding the clinical profiles that influence the concordance of RAS mutations between blood and tissue to guide therapy in metastatic colorectal cancer
29. 1754O - Prediction of serious complications in patients with cancer and pulmonary embolism: Validation of the EPIPHANY index in a prospective cohort of patients from the PERSEO study
30. P-219 - Is there any affordable and reliable score in local gastric cancer?
31. P-190 - Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
32. P-157 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen
33. P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial
34. 669P - Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)
35. 553P - First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study
36. 492P - Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials
37. 677P - Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.